title: Experts condemn "flawed" NICE process over its rejection of prostate cancer drug.
authors.affiliation: London.
authors.forename: Adrian
authors.initials: A
authors.lastname: O'Dowd
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000191:economics*; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D006077:Government Agencies; D006801:Humans; D008297:Male; D009313:National Health Programs; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D006113:United Kingdom
chemical_list: D000736:Androstenes; D000737:Androstenols; C089740:abiraterone